Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ATE.TO
- Price
- -
- Stock movement up
- +- (%)
- Company name
- Antibe Therapeutics Inc.
- Exchange
- (TO ,
- Currency
- CAD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 15.64M
- Ent value
- 34.72M
- Price/Sales
- -
- Price/Book
- 0.60
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 31.65%
- 1 year return
- 136.00%
- 3 year return
- -33.49%
- 5 year return
- -20.00%
- 10 year return
- -14.11%
Last updated: 2024-12-17
DIVIDENDS
ATE.TO does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 0.60 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 53.01M |
| EPS (TTM) | -0.35 |
| FCF per share (TTM) | -0.35 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -19.91M |
| Net income (TTM) | -18.55M |
| EPS (TTM) | -0.35 |
| EPS (1y forward) | -0.45 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 11.34M |
| Net receivables | 0.00 |
| Total current assets | 28.09M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 56.36M |
| Accounts payable | 0.00 |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 2.79M |
| Total liabilities | 30.43M |
| Shareholder's equity | 25.94M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -18.25M |
| Capital expenditures (TTM) | 2.00K |
| Free cash flow (TTM) | -18.25M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -71.53% |
| Return on Assets | -32.92% |
| Return on Invested Capital | -71.53% |
| Cash Return on Invested Capital | -70.35% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| ATE.TO | S&P500 | |
| Current price drop from All-time high | -86.12% | -0.36% |
| Highest price drop | -95.29% | -56.47% |
| Date of highest drop | 26 Jan 2015 | 9 Mar 2009 |
| Avg drop from high | -65.69% | -11.07% |
| Avg time to new high | 50 days | 12 days |
| Max time to new high | 2565 days | 1805 days |
COMPANY DETAILS
Marketcap
15.64M
Marketcap category
Small-cap
Description
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.
Employees
11
Website
Investor relations
-
SEC filings
CEO
Country
Canada
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found